Skip to content

Home
About Us
- Team
- Job Openings
Antivirals
- BK Virus
Immuno-Oncology
Pledge AI
News & Presentations
- News
- Presentations

Home
About Us
- Team
- Job Openings
Antivirals
- BK Virus
Immuno-Oncology
Pledge AI
News & Presentations
- News
- Presentations

Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus

By November 10, 2025

PrevPreviousConformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

Our discovery platform can tailor novel and clinically relevant compounds for some of the most exciting targets that remain out of therapeutic reach.

CAREERS

Are you a passionate and driven professional seeking a new opportunity? See our recent job openings.

NORTH AMERICA

45 Dan Rd., Ste. 382
Canton, MA 02021
USA

+1 339-502-8643

info@pledge-tx.com

EUROPE

Gaston Geenslaan 1
3001 Leuven
Belgium

+32 16 85 26 80

info@pledge-tx.com

Linkedin Twitter

© 2026 Pledge Therapeutics. All rights reserved

Biotech Website Design

Home
About Us
- Team
- Job Openings
Antivirals
- BK Virus
Immuno-Oncology
Pledge AI
News & Presentations
- News
- Presentations

Home
About Us
- Team
- Job Openings
Antivirals
- BK Virus
Immuno-Oncology
Pledge AI
News & Presentations
- News
- Presentations

Linkedin Twitter